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LETTERS TO THE EDITOR
CMV Retinitis
Diagnosis by Non-
ophthalmologists:
Learning Curve
Over a 4-Day
Training Workshop
To the Editors:
Cytomegalovirus (CMV) retinitis is
a blinding opportunistic infection that
primarily affects people with AIDS in
resource-limited settings. Screening for
CMV retinitis is important because the
infection can cause irreversible retinal
destruction before the onset of visual
symptoms. Routine screening is recom-
mended for patients with CD4 counts less
than 100 cells per microliter and consists
of a dilated fundus examination with
an indirect ophthalmoscope. However,
screening rarely occurs in low- and
middle-income countries because ophthal-
mologists are usually not available. As
a result, clinical outcomes are poor, with
roughly one-third of eyes already blind by
the time they are diagnosed with CMV
retinitis.1
Given the lack of CMV retinitis
screening for its HIV population, the
Médecins Sans Frontières Yangon Project
initiated a program in 2006 to train its
AIDS physicians how to diagnose and
treat CMV retinitis at the point-of-care.2
An outside ophthalmologist (D.H.) de-
signed and implemented a 4-day training
program to transfer the skills of binocular
indirect ophthalmoscopy for CMV retinitis
diagnosis. The workshop has been
repeated every year since. In this study,
we retrospectively reviewed the records
from 2 of the workshops to determine the
sensitivity and speciﬁcity of CMV retinitis
diagnosis by non-ophthalmologists over
the course of a 4-day training workshop.
METHODS
Two training workshops, each at-
tended by 5 different HIV/AIDS physi-
cians, were administered over 2
consecutive weeks in Yangon, Myanmar,
in February 2012. The 4-day training
workshop is described in detail else-
where.2 Brieﬂy, the workshop consisted
of didactic lectures about retinal diseases,
instruction in the use of the binocular
indirect ophthalmoscope, and practical
sessions using the indirect ophthalmo-
scope—ﬁrst on model eyes and then on
patients with AIDS. Two of the trainees
had completed the workshop before 1–2
years and had been performing indirect
ophthalmoscopy at their respective clinics
in the interim. The remaining physicians
had no experience with indirect ophthal-
moscopy. All were medical school grad-
uates with 1 to 5 years of experience in
general medical practice; all had been
working in clinics dedicated to patients
with HIV/AIDS for at least 1 year. The
workshops were led by 3 ophthalmolo-
gists and included both classroom didac-
tics and clinical examinations of patients
with HIV/AIDS.2 During clinical exami-
nations, trainees and ophthalmologists
recorded on a standardized form whether
each eye had CMV retinitis (present,
absent, unknown). By workshop design,
each trainee and ophthalmologist was
masked to the results of each other’s
examination until everyone had examined
a particular patient, at which time one of
the ophthalmologists would review the
ﬁndings of that patient and provide
directed guidance to trainees.
We assessed agreement between the
3masked ophthalmologists with a Cohen’s
kappa statistic. For subsequent analyses,
we constructed a consensus diagnosis,
deﬁned as the diagnosis agreed on by at
least 2 ophthalmologists. We modeled the
sensitivity of indirect ophthalmoscopy
over the 4 days of the workshop using
mixed effects linear regression with trainee
as a random effect and using only the
subset of eyes classiﬁed as having CMV
retinitis by the consensus grade. We used
a similar model to estimate: (1) speciﬁcity,
using the subset of eyes classiﬁed as not
having CMV retinitis by the consensus
diagnosis and (2) the rate of indeterminate
tests, separately for patients with and
without the consensus diagnosis of CMV
retinitis. We constructed 95% conﬁdence
intervals for all statistical tests using boot-
strapping (1000 replications), with resam-
pling at the patient level to account for
nonindependence of eyes. We used Stata
12 (Statacorp, College Station, TX) for all
analyses. The study was reviewed by the
University of California, San Francisco
Committee for Human Research, which
deemed that the study did not require
ethical approval because it used retrospec-
tive deidentiﬁed data.
RESULTS
Of 171 eyes examined by trainees,
89 were examined by all 3 ophthalmol-
ogists. Agreement between the 3 oph-
thalmologists was high for the diagnosis
of CMV retinitis (k = 0.85, 95% CI:
0.77 to 0.91).
We constructed a consensus diag-
nosis for CMV retinitis for the 147
examinations where at least 2 ophthal-
mologists agreed. Of these 147 eyes,
CMV retinitis was present by ophthal-
mologist consensus in 89 (60.5%). For
those eyes with a consensus diagnosis of
CMV retinitis, novice trainees demon-
strated a remarkable improvement in the
ability to detect CMV retinitis over the 4
days of the workshop (from 25.1% to
83.9%; P , 0.001), as well as a reduc-
tion in the number of diagnoses coded as
“unknown” (from 46.7% to 7.5%; P =
0.002) (Fig. 1A). In contrast, experi-
enced trainees had near perfect sensitiv-
ity throughout the entire 4 days of the
workshop and no evidence for change
during the workshop (P = 0.62 for CMV
retinitis diagnoses and P = 0.40 for
“unknown” diagnoses; Fig. 1B).
Of 58 eyes without CMV retinitis
by consensus diagnosis, novice trainees
had a relatively high rate of correct
diagnosis early in the week, which dem-
onstrated a slight but nonsigniﬁcant reduc-
tion throughout the 4 days (from 79.7% to
62.0%; P = 0.16) and was accompanied by
a relatively stable rate of “unknown”
diagnoses (P = 0.72) (Fig. 1C). The
experienced trainees showed a similar pat-
tern, with near perfect speciﬁcity early in
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the week that decreased nonsigniﬁcantly
throughout the 4 days of the workshop
(from 97.7% to 75.8%; P = 0.08) and was
accompanied by a nonsigniﬁcant slightly
increased rate of “unknown” diagnoses
(from 2.0% to 10.7%; P = 0.24) (Fig. 1D).
DISCUSSION
Our data show that non-
ophthalmologists with no prior experi-
ence in eye examination can quickly
learn indirect ophthalmoscopy, with
enough skill to diagnose CMV retinitis
with high accuracy. Physicians who had
learned indirect ophthalmoscopy at
a prior workshop and had been examin-
ing patients in the interim maintained
their diagnostic accuracy at a high level.
The steep learning curve observed
in this study may owe itself in part to the
obvious clinical ﬁndings of CMV reti-
nitis, as well as the high probability that
any retinal abnormality in a patient with
AIDS is due to CMV infection.3 More-
over, because only trainees who had
voiced interest in the program were
selected for the workshop, the trainees
were by deﬁnition highly motivated to
learn indirect ophthalmoscopy.
This study supports the idea that
HIV/AIDS clinicians can diagnose CMV
retinitis in settings with poor access to
ophthalmologists. Once diagnosed, the
HIV provider could institute oral
valganciclovir if available or could
even perform intravitreal ganciclovir
injections.2,4 With proper training and
monitoring, HIV/AIDS physicians can
provide primary management of CMV
retinitis, just as they do all other oppor-
tunistic infections.
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FIGURE 1. Sensitivity and specificity of trainee diagnosis of CMV retinitis over a 4-day indirect ophthalmoscopy training course in
Myanmar. A and B, Depict sensitivity over time by showing the proportion of eyes diagnosed with CMV retinitis by ophthalmologist
consensus that were diagnosed with CMV retinitis (green) or not given a diagnosis (red) by inexperienced (A) and experienced (B)
trainees. C and D, Depict specificity by showing the proportion of eyes with no CMV retinitis by ophthalmologist consensus that were
diagnosed as not having CMV retinitis (blue) or not given a diagnosis (red) by inexperienced (C) and experienced (D) trainees.
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Nationwide Study of
Cancer in HIV-Infected
Taiwanese Children
in 1998–2009
To the Editors:
We previously reported an
increased incidence of cancers in a nation-
wide registry of 15,269 HIV/AIDS pa-
tients in Taiwan in 1998–2009.1 Excluded
from that cohort were HIV-infected pa-
tients younger than 15 years. In this study,
we determined the cancer incidence in this
group of HIV-infected children and com-
pared their incidence to that of noninfected
children in the general population.
With approval from the National
Health Research Institutes, Taiwan, the
National Health Insurance Research Data-
base (NHIRD) was searched for children
younger than 15 years with HIV/AIDS in
the 1998–2009 databases as previously
described.1 Patients subsequently diag-
nosed with cancer were identiﬁed based
on the ICD-9-CM diagnosis codes. To
calculate expected rates of cancer, data
were obtained from a database linked by
the Ofﬁce of Statistics of the Department
of Health using the NHIRD and death
certiﬁcate database. This data set consisted
of 1.8 million individuals randomly sam-
pled from the Registry for Beneﬁciaries of
the NHIRD, which contains registration
and original claim data of every person
who was a beneﬁciary of the National
Health Insurance program during the
period 1998–2009 (approximately 23.72
million individuals). All individuals under
the age of 15, totaling 297,387 individuals,
were then selected as the control group.
The incidence density (ID) and
standardized incidence rate (SIR) for
each cancer type were calculated.
Person-years analysis was performed in
strata of age, calendar period, and cancer
type to estimate the ID and SIR. The start
date for the calculation of person-years
was the date of ﬁrst HIV/AIDS clinic
visit and the end date was December 31,
2009, as no deaths occurred during the
follow-up period. The ID of each type of
cancer after HIV infection was calculated
by dividing the number of observed
cancer cases by the total person-years at
risk for that cancer. The SIR for each
cancer type was calculated by dividing
the observed number of cases by the
number that would be expected if age-,
sex-, and calendar period–speciﬁc rates
of the comparison population applied.2
The 95% conﬁdence interval (CI) was
calculated by Poisson distribution. All
analyses were conducted using SAS
version 9.2 (SAS Institute Inc., Cary,
NC). A 2-tailed P value of ,0.05 was
considered statistically signiﬁcant.
A total of 230 HIV-infected children
were identiﬁed. There were 131 males and
99 females. Seven of these children were
diagnosed with cancer (Table 1). When
compared with non–HIV-infected chil-
dren, increased SIRs were seen in HIV-
infected children with Kaposi sarcoma
(SIR = 30,513.7, 95% CI: 3426.89 to
110,169.44), cancer of the lung and
bronchus (SIR = 108.32, 95% CI: 1.42
to 602.67), and cancer of the testis (SIR =
106.86, 95% CI: 1.4 to 594.53).
Most of the reported cases of cancer
in children with HIV are AIDS-deﬁning
cancers such as Kaposi sarcoma and
Non-Hodgkin lymphoma or non–AIDS-
deﬁning cancers such as leukemia. Our
study showed cancers of the lung and testis,
which are very uncommon in children. A
case of primary lung cancer in a child with
AIDS was previously reported by Biggar
et al.3 This study identiﬁed the ﬁrst case of
testicular cancer in a child with HIV.
Unfortunately, the histopathology of the
testicular tumor in this child is unknown.
The only previous study in Asia
was performed in Thailand, which
reported a 10-time higher incidence of
cancers in HIV-infected children com-
pared with non–HIV-infected children,
but this study was performed in children
born before perinatal antiretroviral ther-
apy.4 In the advent of antiretroviral
therapy, the incidence of AIDS-deﬁning
cancers in children has decreased dramat-
ically5 but that of non–AIDS-deﬁning
cancers has continued to rise. Epidemi-
ologic data suggest that antiretroviral
therapy may reduce the incidence of
AIDS-deﬁning cancers in children
because of improved immunosurveil-
lance induced by antiretroviral ther-
apy.6,7 However, immune dysregulation
has been reported to persist in some
children on antiretroviral therapy.8,9 A
limitation of this study was that there
were no perinatal antiretroviral therapy
exposure data, as these data would
help conﬁrm whether the cancer inci-
dence was related to antiretroviral expo-
sure. Many of the cancers have been
associated with an infectious etiology in
HIV-infected adults1 and children.10
Although a causal role has not yet
been established for some cancers,
human papilloma virus (HPV) infection
has been associated with lung cancer11
and testicular cancer12 in adults.
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